Á lódáil...
Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy
Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60 years old have a 5-year survival rate of less than 8%. In an attempt to improve this, epigenetic modifying agents have been combined as therapies in clinical studies. In particular combinations with Decitabine and V...
Na minha lista:
| Foilsithe in: | Oncotarget |
|---|---|
| Main Authors: | , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Impact Journals LLC
2017
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5584259/ https://ncbi.nlm.nih.gov/pubmed/28881658 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18009 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|